Development of A Multi-Modality System for Onco-Imaging

肿瘤成像多模态系统的开发

• 批准号: 7669183
• 负责人: GULTEKIN GULSEN
• 金额: $ 47.11万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7669183
• 关键词: Academia; Accounting; Adenocarcinoma; Algorithms; Animals; Anxiety; Area; Benign; Biopsy; Blood; Blood Vessels; Carcinogens; Cicatrix; Clinical; Clinical Trials; Collaborations; Contrast Media; Data; Detection; Development; Devices; Diagnostic Specificity; Differential Diagnosis; Diffusion; Equation; Ethylnitrosourea; Evaluation; Frequencies; Functional Imaging; Future; Goals; Hemoglobin; Human; Hybrids; Image; Imaging technology; Industry; Internal Breast Prosthesis; Ions; Kidney; Kinetics; Lead; Lesion; Literature; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Mammary Ultrasonography; Maps; Measures; Methods; Modality; Modeling; Modification; Molecular; Molecular Probes; Molecular Weight; Mono-S; Nature; Optical Tomography; Optics; Outcome; Oxygen; Patients; Performance; Permeability; Phase; Polymers; Preparation; Property; Proteins; Protocols documentation; Rattus; Reporting; Research; Resolution; Role; Scheme; Screening procedure; Sensitivity and Specificity; Site; Specificity; Staging; System; Techniques; Technology; Testing; Time; Tissues; Toxic effect; Translational Research; Universities; Validation; Woman; absorption; albumin-(gadolinium-DTPA); angiogenesis; base; bioimaging; breast lesion; cancer diagnosis; clinical application; data acquisition; design; detector; diagnostic accuracy; diffuse optical tomography; extracellular; high risk; imaging modality; improved; in vivo; interstitial; malignant breast neoplasm; member; novel; optical imaging; performance tests; phantom model; prototype; reconstruction; research study; subcutaneous; technology development; tissue oxygenation; tool; tumor; uptake; validation studies

DESCRIPTION (provided by applicant): Recently, the optical imaging field has been rapidly expanding in scope through the use of new exogenous molecular probes. We have already developed a multi-frequency & multi- spectral optical tomography animal imaging system and integrated to an MRI system. In this application, we will expand our hybrid system to measure dynamic information from exogenous probes. This system would measure the enhancement kinetics of the bi-functional MR/NIR or mono-functional NIR contrast agents in addition to the endogenous contrast due to hemoglobin contents and scattering properties. There are two main phases of the proposal. The first and the foremost phase is the technology development, which can be classified into two sub aims: a) the development of a novel multi-modality dynamic imaging system and b) the development of polymer based bi-functional and mono-functional NIR agents. We believe that such a hybrid system will facilitate the development of new contrast agents for biomedical imaging and that the development of polymer based molecular agents will provide a potential new molecular platform for these new contrast agents. In the second phase of the proposal, we will try to utilize this novel hybrid system together with a small molecular MR and a medium size (~30-40 kDa) novel polymer based optical agent. We will compare the role of all kinetic parameters and intrinsic properties obtained by MR/Optical imaging system, individually or combined, in cancer diagnosis after completing all analysis steps. Thus, we will be able to test our hypothesis that "the parameters obtained by macromolecular optical agent together with total hemoglobin, oxygen saturation and tissue scattering parameters can achieve a higher specificity in differentiating between ENU induced malignant and benign tumors compared to MRI parameters measured by low molecular weight extracellular MRI agents". We believe our collaboration with GE Global Research Center for the development of the novel MR/NIR contrast agents will serve to close the gap between the academia and the industries further for biomedical imaging applications. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors. With appropriate modifications in design, the proposed MR/Optical technology has a great translational potential for future human clinical trials. This application is aimed at developing a hybrid MR/DOT system along with novel polymer based contrast agents. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors.

描述（由申请人提供）：近年来，通过使用新的外源分子探针，光学成像领域的范围迅速扩大。我们已经开发了一套多频多光谱光学断层动物成像系统，并集成到MRI系统中。在这个应用中，我们将扩展我们的混合系统来测量来自外源探针的动态信息。该系统将测量双功能MR/NIR或单功能NIR造影剂的增强动力学，以及由血红蛋白含量和散射特性引起的内源性造影剂。该提案主要分为两个阶段。第一个也是最重要的阶段是技术开发，可分为两个子目标：a)开发新的多模态动态成像系统；b)开发基于聚合物的双功能和单功能近红外剂。我们相信这种混合系统将促进生物医学成像新型造影剂的发展，而聚合物基分子造影剂的发展将为这些新型造影剂提供一个潜在的新分子平台。在提案的第二阶段，我们将尝试将这种新型混合系统与小分子MR和中等尺寸（~30-40 kDa）新型聚合物基光学剂一起使用。在完成所有分析步骤后，我们将比较MR/光学成像系统获得的所有动力学参数和内在特性，单独或联合，在癌症诊断中的作用。因此，我们将能够验证我们的假设，即“与低分子量细胞外MRI剂测量的MRI参数相比，大分子光学剂获得的参数与总血红蛋白、氧饱和度和组织散射参数在鉴别ENU诱导的恶性肿瘤和良性肿瘤方面具有更高的特异性”。我们相信，我们与GE全球研究中心在新型MR/NIR造影剂开发方面的合作将有助于进一步缩小学术界与生物医学成像应用行业之间的差距。如果成功，我们的努力结果将提供一个复杂的工具，可以提供高灵敏度和高特异性的检测和表征肿瘤。通过适当的设计修改，所提出的MR/光学技术在未来的人体临床试验中具有巨大的转化潜力。该应用旨在开发一种混合MR/DOT系统以及新型聚合物基造影剂。如果成功，我们的努力结果将提供一个复杂的工具，可以提供高灵敏度和高特异性的检测和表征肿瘤。